Oral-Absorption-Enhancing Drug-Delivery Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Oral-Absorption-Enhancing Drug-Delivery Technology
The authors examine an oral-absorption-enhancement technology based on surface-active materials to increase apical membrane fluidity in vitro.


Pharmaceutical Technology
Volume 35, pp. s12-s14

Conclusion

The GIPET technology is an advanced-stage permeation enhancement oral drug-delivery platform based on enhancers that have been studied in cells, tissues, rodents, dogs, and humans to demonstrate their ability to promote drug absorption, safety, reversibility, and mechanism of action. The technology is suitable for a wide range of different molecule types as evidenced by the preclinical and clinical studies showing enhanced intestinal absorption.

Acknowledgments

The authors thank David Brayden, professor at the University College Dublin in Ireland for critical reading of the manuscript. The authors also want to acknowledge that the work of Edwin Walsh is funded by an Irish Research Council for Science, Engineering and Technology (IRCSET)–Industry Partnership between the Irish Government and Merrion Pharmaceuticals.

Edwin G. Walsh, BSc, is a PhD student at the School of Veterinary Medicine and Conway Institute, University College Dublin, in Dublin, Ireland. Alan P. Cullen, MSc, is preclinical development manager, John S. Fox, PhD, MBA, is chief development officer, and Thomas W. Leonard*, RPh, PhD, is vice-president and chief scientific officer, all at Merrion Pharmaceuticals, 219 Racine Drive, Suite D, Wilmington, NC 28403, tel. 910.799.1847, fax 910.395,1843,
.

References

1. E. Windsor and G.E. Cronheim, Nature 190 (4772), 263–264 (1961).

2. M. Hayashi, M. Tomita, and A. Awazu, Adv. Drug Deliv. Rev. 28 (2), 191–204 (1997).

3. T. Lindmark, T. Nikkila, and P. Artursson, J. Pharmacol. Exp. Ther. 275 (2), 958–964 (1995).

4. H. Huang and R.E. Verall, J. Solution Chem. 26 (2) 135–162 (1997).

5. Y. Lo and J. Huanh, Biochem. Pharmacol. 59 (6), 665–672 (2000).

6. JECFA, 29th Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series No. 733 (1986).

7. L. Blomquist, Gastroenterol. 32 (8), 805–812 (1997).

8. A.J. Ryan, R-T. Chang, and C.V. Gisolfi, Med. & Sci. in Sports & Exerc. 28 (6), 698–705 (1996).

9. T.T. Kararli, Biopharm. Drug Dispos. 16 (5), 351–380 (1995).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here